JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Blueprint Medicines (NASDAQ:BPMC) and maintained a price target of $114.
August 07, 2023 | 12:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Blueprint Medicines' stock rating has been reiterated as Market Outperform by JMP Securities, with a maintained price target of $114.
The reiteration of the Market Outperform rating and maintained price target by JMP Securities indicates a positive outlook for Blueprint Medicines. This could potentially lead to an increase in investor confidence and a positive impact on the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100